Expedited Investigational New Drug Pilot Program; Request for Information
Health and Human Services Department · Notice
Summary
The Food and Drug Administration (FDA or the Agency) is opening a public docket to solicit input and comments on a proposal to establish a pilot program, the Expedited Investigational New Drug (IND) pilot program, to shorten the time it takes from drug identification to first-in-human (FIH) study, while protecting clinical trial participants. FDA is requesting information on the potential pilot program which would establish a network of qualified research institutions, such as academic medical centers (AMCs), healthcare networks (HNs), contract research organizations (CROs), regulatory advisors, and/or other research or third-party review organizations (collectively called Qualified Research Institutions, or "QRIs"), who would partner with sponsors to develop and review protocols for FIH clinical trials intended for a IND submission to FDA. Information provided through this public docket will help the Agency refine our approach and consider other opportunities to accelerate time to FIH clinical trials.
Affected frameworks & controls
No framework controls are mapped to this item yet.
Key dates
- Status
- Active
- Category
- HealthcareHIPAA
- Published
- Jun 24, 2026
- Effective
- —
- Comments close
- Jul 22, 2026
View source document Download PDF